Sanpraz tablets p / o 40mg, No. 10

• peptic ulcer of the stomach or duodenum in the acute phase;

• erosive gastritis (including those associated with Helicobacter pylori);

• erosive and ulcerative lesions of the stomach and duodenum associated with the intake of NSAIDs;

• reflux esophagitis

For gastric ulcer and duodenal ulcer, erosive gastritis, the drug is prescribed at 40-80 mg / day. The course of treatment for exacerbation of duodenal ulcer is 2 weeks, and gastric ulcer - 4-8 weeks.

For the prevention of exacerbations of gastric ulcer and duodenal ulcer , 20 mg / day is prescribed.

For the eradication of Helicobacter pylori, take 40 mg 2 times / day in combination with antimicrobial agents. The course of therapy is 7-14 days.

For erosive and ulcerative lesions of the stomach and duodenum associated with the intake of NSAIDs, appoint 40-80 mg / day. The course of treatment is 4-8 weeks. For the prevention of erosive lesions against the background of prolonged use of NSAIDs - 20 mg / day.

With reflux esophagitis, appoint 20-40 mg / day. The course of therapy is 4-8 weeks. For the prevention of exacerbations, take 20 mg / day.

In patients with severely impaired liver function, the dose should be reduced to 40 mg once every 2 days, while it is necessary to monitor the biochemical parameters of the blood. With an increase in the activity of liver enzymes, the drug should be canceled.

The tablets are taken orally whole (without crushing or dissolving), drinking a sufficient amount of liquid. The drug is recommended to be taken 1 hour before breakfast, with a frequency of 2 times / day the second dose - 1 hour before dinner.

Active substance:

pantoprazole sodium sesquihydrate - 45.1 mg,

which corresponds to the content of pantoprazole - 40 mg

Excipients:

magnesium oxide - 18 mg, calcium carbonate - 81.4 mg, crospovidone - 35 mg, sodium lauryl sulfate - 5 mg, calcium stearate - 3 mg, colloidal silicon dioxide - 5 mg.

Shell composition:

copolymer of methacrylic acid and ethyl acrylate (1: 1) - 11 mg, triethyl citrate - 1.1 mg, copovidone - 7 mg, talc - 10.7 mg, titanium dioxide (E171) - 0.8 mg, iron oxide yellow (E172) - 0.2 mg, macrogol 6000 - 0.35 mg.

• dyspepsia of neurotic genesis;

• malignant gastrointestinal diseases;

• children's age (due to the lack of data on the use of the drug in pediatric practice);

• hypersensitivity to pantoprazole.

The drug is prescribed with caution in liver failure.

Enteric-coated yellow tablets, round, biconvex.

Composition:

Active substance:

pantoprazole sodium sesquihydrate - 45.1 mg,

which corresponds to the content of pantoprazole - 40 mg

Excipients:

magnesium oxide - 18 mg, calcium carbonate - 81.4 mg, crospovidone - 35 mg, sodium lauryl sulfate - 5 mg, calcium stearate - 3 mg, colloidal silicon dioxide - 5 mg.

Shell composition:

copolymer of methacrylic acid and ethyl acrylate (1: 1) - 11 mg, triethyl citrate - 1.1 mg, copovidone - 7 mg, talc - 10.7 mg, titanium dioxide (E171) - 0.8 mg, iron oxide yellow (E172) - 0.2 mg, macrogol 6000 - 0.35 mg.

Clinical and pharmacological group: N + -K + -ATPase inhibitor. Antiulcer drug

Pharmaco-therapeutic group: Proton pump inhibitor

pharmachologic effect

Inhibitor of H + -K + -ATPase. Blocks the final stage of secretion of hydrochloric (hydrochloric) acid, reduces the level of basal and stimulated (regardless of the type of stimulus) secretion of hydrochloric (hydrochloric) acid in the stomach. In case of duodenal ulcer disease associated with Helicobacter pylori, a decrease in gastric secretion increases the sensitivity of the microorganism to antibiotics.

Does not affect gastrointestinal motility. Secretory activity is normalized 3-4 days after the end of the drug intake.

Pharmacokinetics

Suction

After taking the drug inside, pantoprazole is rapidly absorbed from the gastrointestinal tract. Cmax is reached after 2.5 hours and is 2-3 mg / l, while the Cmax value remains unchanged after repeated administration. Bioavailability 65-77%.

Withdrawal

T1 / 2 - about 1 hour

Indications

• peptic ulcer of the stomach or duodenum in the acute phase;

• erosive gastritis (including those associated with Helicobacter pylori);

• erosive and ulcerative lesions of the stomach and duodenum associated with the intake of NSAIDs;

• reflux esophagitis

Dosage regimen

For gastric ulcer and duodenal ulcer, erosive gastritis, the drug is prescribed at 40-80 mg / day. The course of treatment for exacerbation of duodenal ulcer is 2 weeks, and gastric ulcer - 4-8 weeks.

For the prevention of exacerbations of gastric ulcer and duodenal ulcer , 20 mg / day is prescribed.

For the eradication of Helicobacter pylori, take 40 mg 2 times / day in combination with antimicrobial agents. The course of therapy is 7-14 days.

For erosive and ulcerative lesions of the stomach and duodenum associated with the intake of NSAIDs, appoint 40-80 mg / day. The course of treatment is 4-8 weeks. For the prevention of erosive lesions against the background of prolonged use of NSAIDs - 20 mg / day.

With reflux esophagitis, appoint 20-40 mg / day. The course of therapy is 4-8 weeks. For the prevention of exacerbations, take 20 mg / day.

In patients with severely impaired liver function, the dose should be reduced to 40 mg once every 2 days, while it is necessary to monitor the biochemical parameters of the blood. With an increase in the activity of liver enzymes, the drug should be canceled.

The tablets are taken orally whole (without crushing or dissolving), drinking a sufficient amount of liquid. The drug is recommended to be taken 1 hour before breakfast, with a frequency of 2 times / day the second dose - 1 hour before dinner.

Side effect

From the side of the central nervous system: headache; very rarely - depression, weakness, dizziness, visual impairment.

From the digestive system: diarrhea, nausea, pain in the upper abdomen, constipation, flatulence; in isolated cases (1 case per 106 patients) - severe hepatocellular liver damage with jaundice, liver dysfunction.

Allergic reactions: skin rash, itching, flushing of the skin, anaphylactic reactions (up to shock).

Others: painful tension of the mammary glands, hyperthermia.

Contraindications for use

• dyspepsia of neurotic genesis;

• malignant gastrointestinal diseases;

• children's age (due to the lack of data on the use of the drug in pediatric practice);

• hypersensitivity to pantoprazole.

The drug is prescribed with caution in liver failure.

Application during pregnancy and lactation

The drug is prescribed with caution during pregnancy and lactation (breastfeeding).

Application for violations of liver function

In patients with severely impaired liver function, the dose should be reduced to 40 mg once every 2 days, while it is necessary to monitor the biochemical parameters of the blood. With an increase in the activity of liver enzymes, the drug should be canceled.

Application in children

Contraindication: children's age (due to the lack of data on the use of the drug in pediatric practice).

special instructions

Before and after the end of therapy, endoscopic control (if necessary, with a biopsy) is required to exclude malignant neoplasms of the stomach or esophagus. the use of the drug may delay the correct diagnosis.

Overdose

Data on overdose of the drug Sanpraz are not provided.

Drug interactions

With the simultaneous use of pantoprazole can reduce the absorption of drugs, the bioavailability of which depends on the pH of the stomach (for example, ketoconazole).

Storage conditions

The drug should be stored in a dry, dark place, out of the reach of children, at a temperature not exceeding 25 ? C.

Shelf life

Shelf life is 3 years.

Terms of sale

The drug is available with a prescription.